The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
CassidyJ., TaberneroJ., TwelvesC.XELOX (Capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.J Clin Oncol.2004; 22(11): 2084–2091.
2.
ShieldsA.F., ZalupskiM.M., MarchallJ.L., MeropolN.J.Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine.Cancer.2004; 100(3): 531–537.
3.
PfeifferP., HahnP., JensenH.A.Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer.Acta Oncol.2003; 42(8): 832–836.
4.
ScheithauerW., KornekG.V., RadererM.Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.J Clin Oncol.2003; 21(7): 1307–1312.
5.
SumpterK., Harper-WynneC., CunninghamD., GillbanksA., NormanA.R., HillM.Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience.Clin Oncol (R Coll Radiol).2003; 15(5): 221–226.
6.
BornerM.M., DietrichD., StuppR.Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.J Clin Oncol.2002; 20(7): 1759–1766.
7.
Diaz-RubioE., EvansT.R., TaberneroJ.Capecitabine (Xeloda) in combination with oxaliplatin: a phase I dose-escalation study in patients with advanced or metastatic solid tumors.Ann Oncol.2002; 13(4): 558–565.
8.
RödelC., GrabenbauerG.G., PapadopoulosT., HohenbergerW., SchmallH.J., SauerR.Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer.J Clin Oncol.2003; 21(16): 3098–3104.
9.
GrotheyA., JordanK., KellnerO.Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer.Proc Am Soc Clin Oncol.2003; 22: 255(abstract 1022).
10.
JordanK., GrotheyA., KellnerO.Randomized phase II trial of capecitabine plus irinotecan vs capecitabine plus oxaliplatin as first-line therapy in advanced colorectal cancer (ACRC): results of an interim analysis.Proc Am Soc Clin Oncol.2002; 21: abstract 2225.
11.
ZeuliM., NardoniC., PinoM.S.Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer.Ann Oncol.2003; 14(9): 1378–1382.
12.
ScheithauerW., KornekG.V., RadererM.Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.Ann Oncol.2002; 13(10: 1583–1589.
13.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. Available at: http://www.nccn.org/. Accessed on April 26, 2005.
14.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol.1997; 15(1): 103–109.
15.
BrandiG., PantaleoM.A., GalliC.Hypersensitivity reactions related to oxaliplatin (OHP).Br J Cancer.2003; 89: 477–481.
16.
QureshiK.M., LeichmanC., BerdzikJ.Incidence of hypersensitivity reactions to oxaliplatin (OXP) at Roswell Park Cancer Institute (RPCI) and protocol for desensitization.Proc Am Soc Clin Oncol.2003; 22: 789 (abstract 3173).
17.
DoldF., HoeyD., CarberryM., MusketA., FriedbergV., MitchellE.Hypersensitivity in patients with metastatic colorectal carcinoma undergoing chemotherapy with oxaliplatin.Proc Am Soc Clin Oncol.2002; 21: 370A (abstract 1478).
LymanG.H.Balancing the benefits and costs of colony-stimulating factors: a current perspective.Semin Oncol.2003; 30(suppl 13): 10–17.
20.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.J Clin Oncol.2000; 18(20): 3558–3585.
21.
KretzschmarA., Thuss-PatienceP.C., PinkD.Extravasations (E) of oxaliplatin (O).Proc Am Soc Clin Oncol.2002; 21(abstract 2900).
22.
BensonA.B., AjaniJ.A., CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea.J Clin Oncol.2004; 22: 2918–2926.
23.
GamelinE., GamelinL., BossiL., QuasthoffS.Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.Semin Oncol.2002; 29(suppl 15): 21–33.
24.
GamelinE., GamelinL., DelvaR., Guerin-MeyerV., MorelA., Boisdron-CelleM.Prevention of oxaliplatin peripheral neuropathy by Ca+ gluconate/Mg+ chloride infusions: a retrospective study.Proc Am Soc Clin Oncol.2002; 21: 157A (abstract 624).
25.
TakimotoC.H., RemickS.C., SharmaS.Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute organ dysfunction working group study.J Clin Oncol.2003; 21(14): 2664–2672.
DoroshowJ.H., SynoldT.W., GandaraD.Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.Semin Oncol.2003; 30(suppl 15): 14–19.
28.
Rubbia-BrandtL., AudardV., SartorettiP.Severe hepatic sinsuoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.Ann Oncol.2004; 15(3): 460–466.
29.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapy.Oncologist.2001; 6(2): 162–176.
